Abstract
Numerous therapeutic options have been introduced for metastatic renal cell carcinoma (MRCC) in recent years, including monoclonal antibodies such as bevacizumab and small-molecule tyrosine kinase inhibitors such as sunitinib and sorafenib. Similarly, several other small-molecule inhibitors-including imatinib, dasatinib, and nilotinib-have been approved for the treatment of chronic myelogenous leukemia (CML). The combination of these targeted agents is an area of intense clinical investigation. Here, we describe a patient diagnosed with MRCC)while on imatinib therapy for cml. Treatment of this patient with the combination of bevacizumab and imatinib led to a 6-month period of stable disease, with no treatment-related adverse events. More extensive clinical exploration of this combination of agents may therefore be warranted.
Highlights
CASE PRESENTATIONUpon abdominal computed tomography (ct) imaging performed to rule out nephrolithiasis, a 57-year-old woman was incidentally found to have a 5-cm renal mass
Numerous therapeutic options have been introduced for metastatic renal cell carcinoma in recent years, including monoclonal antibodies such as bevacizumab and small-molecule tyrosine kinase inhibitors such as sunitinib and sorafenib
2.1 Targeted Therapy for mrcc and cml Chronic myelogenous leukemia and metastatic renal cell carcinoma represent two disorders whose therapies have been revolutionized by the advent of targeted agents
Summary
Upon abdominal computed tomography (ct) imaging performed to rule out nephrolithiasis, a 57-year-old woman was incidentally found to have a 5-cm renal mass. The patient subsequently underwent a rightsided nephrectomy, and pathology analysis of the surgical specimen revealed a 5-cm Fuhrman grade 2 clear-cell-type renal cell carcinoma. Imaging by ct of the chest, abdomen, and pelvis at that time showed no evidence of distant disease, and the patient was followed clinically by her urologist. 2 years later, the patient presented to her primary care practitioner with vague complaints of fatigue and lethargy. Initial workup included a complete blood count, remarkable for a pronounced leucocytosis (30,000 white cells/μL, normal differential). Subsequent bone marrow examination was consistent with a diagnosis of chronic myelogenous
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
